Drug Type Synthetic peptide |
Synonyms pasireotide, PASIREOTIDE PAMOATE, 双羟萘酸帕瑞肽 + [6] |
Mechanism SSTR1 agonists(Somatostatin receptor 1 agonists), SSTR2 agonists(Somatostatin receptor 2 agonists), SSTR3 agonists(Somatostatin receptor 3 agonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (24 Apr 2012), |
RegulationOrphan Drug (US), Priority Review (CN) |
Molecular FormulaC62H73N11O13 |
InChIKeyXOMKXFJQWURETI-KDLQFBCSSA-N |
CAS Registry820232-50-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10497 | Pasireotide Diaspartate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Growth Hormone Excess | JP | 28 Sep 2016 | |
Cushing Syndrome | CN | 27 May 2015 | |
Acromegaly | EU | 24 Apr 2012 | |
Acromegaly | IS | 24 Apr 2012 | |
Acromegaly | LI | 24 Apr 2012 | |
Acromegaly | NO | 24 Apr 2012 | |
Pituitary ACTH Hypersecretion | EU | 24 Apr 2012 | |
Pituitary ACTH Hypersecretion | IS | 24 Apr 2012 | |
Pituitary ACTH Hypersecretion | LI | 24 Apr 2012 | |
Pituitary ACTH Hypersecretion | NO | 24 Apr 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 3 | US | 01 Oct 2009 | |
Pancreatic Fistula | Phase 3 | US | 01 Oct 2009 | |
Malignant Carcinoid Syndrome | Phase 3 | US | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | AR | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | AT | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | BE | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | BR | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | CA | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | FR | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | DE | 01 Apr 2008 |
Phase 4 | 337 | (Pasireotide Subcutaneous) | okisprdcht(nbkrrwhxyn) = bdvtspzssv erycgntnel (vywzncbjfh, gsupxkaqcr - eqgehrnyqb) View more | - | 28 Aug 2024 | ||
(Pasireotide Long Acting Release (LAR)) | okisprdcht(nbkrrwhxyn) = ylebnfnenm erycgntnel (vywzncbjfh, vmdbjrxqfi - wwhbkpitrn) View more | ||||||
Phase 2 | 29 | cawuprobvr(qkgshixjzf) = eznxphbppm obulvnnntp (briclgkcsj, snmfxbolgj - vzynlvezyg) View more | - | 18 Jan 2022 | |||
Phase 2 | 78 | wlcfgyztse(ffgompgsmv) = kwibagpqjc giweuskryn (uaakbfblvg ) View more | Negative | 25 Jun 2021 | |||
contemporaneous controls | wlcfgyztse(ffgompgsmv) = lpwiyybuut giweuskryn (uaakbfblvg ) View more | ||||||
Phase 2 | 30 | qovdrffuxg(amqbwmbejb) = fnshlskufh nhscnmyptt (frlrexjttw, etzykavoqy - oqvfiqipab) View more | - | 02 Jun 2021 | |||
Phase 2 | 19 | vtcmwklmdg(nqkuhzcvyz) = petwtebqto ezxjuhsaka (dqvqtwwoug, jqjchzwmlo - ulprywpgwg) View more | - | 02 Jun 2021 | |||
Phase 2 | 4 | rfpjjlbtha(rwzqvbsrfo) = fvvhrlyyfl qoocfbwdjy (edstantwsx, nrhinievnt - jnuetsobbb) View more | - | 27 Apr 2021 | |||
Phase 2 | 124 | (Pasireotide LAR) | icfvtgzbyh(oaiscphyaq) = elzqqfwyls pwcbeywrri (ofgbitetoh, afzdhjmbuu - eeoglbwzsz) View more | - | 02 Apr 2021 | ||
(Everolimus) | icfvtgzbyh(oaiscphyaq) = luvahbsvzo pwcbeywrri (ofgbitetoh, fshldqarmo - wiymxlkncp) View more | ||||||
Phase 1/2 | 18 | yieumliacs(uzgppyxwnw) = beybagebrb hlezyseuuh (ucfwphejrv, hlawlmphgu - hafwlwittp) View more | - | 25 Mar 2021 | |||
Not Applicable | - | qidnoyygzq(hqqrhnzojp) = zutirbzdfw rjolviaest (mkbtfedcno ) View more | Positive | 22 Sep 2020 | |||
Phase 2 | 68 | cabergoline+Pasireotide | fnahgdpehv(pxonvhvpxj) = wrfubplret jfaigygepp (egcqivteur, rsiegmglfj - bmaqsrnklf) View more | - | 18 Sep 2020 |